SCHEMBL1713030

SCHEMBL1713030

O=C(C1CCCN(S(=O)(=O)c2ccccc2Cl)C1)N1CCCC1c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.56
POLB P06746 1/20 0.53
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MAPT P10636 3/20 0.49
KMT2A Q03164 3/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.49
MEN1 O00255 1/20 0.49
HTT P42858 1/20 0.49
AKR1C3 P42330 2/20 0.48
AKR1C1 Q04828 1/20 0.48
HSD11B1 P28845 1/20 0.48
FAAH O00519 1/20 0.47
RIPK1 Q13546 1/20 0.47
CCR1 P32246 2/20 0.46
USP2 O75604 1/20 0.46
ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1722857 0.98 CNR1 (0.56) CNR1POLBLMNASMN1; SMN2MAPT
SCHEMBL1712628 0.92 FAAH (0.51) CNR1POLBLMNASMN1; SMN2MAPT
SCHEMBL1713307 0.91 POLB (0.56) CNR1POLBLMNASMN1; SMN2MAPT
SCHEMBL1713229 0.90 POLB (0.55) CNR1POLBLMNASMN1; SMN2MAPT
SCHEMBL1713125 0.89 POLB (0.53) CNR1POLBLMNASMN1; SMN2MAPT
SCHEMBL1712996 0.89 POLB (0.50) CNR1POLBLMNASMN1; SMN2MAPT
SCHEMBL4094978 0.86 LMNA (0.67) CNR1LMNASMN1; SMN2MAPTALDH1A1
SCHEMBL1712578 0.85 POLB (0.54) CNR1POLBLMNASMN1; SMN2MAPT
SCHEMBL1712636 0.84 LMNA (0.67) CNR1LMNASMN1; SMN2MAPTALDH1A1
SCHEMBL5286229 0.84 POLB (0.55) CNR1POLBLMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202888-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-06-19 US claimed
EP-2252587-B1 PIPERIDINE SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-07-20 EP claimed
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-13 US claimed
US-8691846-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2014-04-08 US disclosed
US-8691846-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2014-04-08 US disclosed
US-20130217729-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-08-22 US disclosed
US-20130217729-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-08-22 US disclosed
US-20130217729-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-08-22 US disclosed
US-20120238602-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES KNUST HENNER (DE) 2012-09-20 US disclosed
US-20120238602-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES KNUST HENNER (DE) 2012-09-20 US disclosed
US-20120238602-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES KNUST HENNER (DE) 2012-09-20 US disclosed
US-8202888-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-06-19 US disclosed
US-8202888-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-06-19 US disclosed
US-8202888-B2 Piperidine sulphonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-06-19 US disclosed
EP-2252587-B1 PIPERIDINE SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-07-20 EP disclosed
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-13 US disclosed
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-13 US disclosed
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203736-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES HCRTR2, PER2, HCRTR1 CNR1 15/4885POLB 3190/4885LMNA 3629/4885
US-20120238602-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES HCRTR2, PER2, HCRTR1 CNR1 15/4885POLB 3190/4885LMNA 3629/4885
US-20130217729-A1 PIPERIDINE SULPHONAMIDE DERIVATIVES HCRTR2, PER2, HCRTR1 CNR1 15/4885POLB 3190/4885LMNA 3629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.